GLPwatch
Papers (9189)
Page 36 of 154, ranked by citation count.
- Fluorescent exendin-4 derivatives for pancreatic β-cell analysis.
- Long-acting amylin analogues for the management of obesity.
- Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages.
- Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
- Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg.
- Semaglutide alleviates gut microbiota dysbiosis induced by a high-fat diet.
- Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review.
- Exendin-4 inhibits glucolipotoxic ER stress in pancreatic β cells via regulation of SREBP1c and C/EBPβ transcription factors.
- Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review.
- Liraglutide pretreatment attenuates sepsis-induced acute lung injury.
- Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory Analysis.
- The GLP-1 analog, liraglutide prevents the increase of proinflammatory mediators in the hippocampus of male rat pups submitted to maternal perinatal food restriction.
- The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial.
- Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials.
- Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER).
- The glucose tolerance test in mice: Sex, drugs and protocol.
- Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide.
- Enhancing human islet transplantation by localized release of trophic factors from PLG scaffolds.
- Semaglutide and Tirzepatide for the Management of Weight Recurrence After Sleeve Gastrectomy: A Retrospective Cohort Study.
- Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis.
- Hedonic eating is controlled by dopamine neurons that oppose GLP-1R satiety.
- Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study.
- Dulaglutide exerts beneficial anti atherosclerotic effects in ApoE knockout mice with diabetes: the earlier, the better.
- Long-Acting Neurotensin Synergizes With Liraglutide to Reverse Obesity Through a Melanocortin-Dependent Pathway.
- Liraglutide Improves Forced Vital Capacity in Individuals With Type 2 Diabetes: Data From the Randomized Crossover LIRALUNG Study.
- Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.
- Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide.
- Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight/obese persons with prediabetes.
- Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review.
- Dosing rationale for liraglutide in type 2 diabetes mellitus: a pharmacometric assessment.
- Role of liraglutide in brain repair promotion through Sirt1-mediated mitochondrial improvement in stroke.
- Liraglutide suppresses obesity and induces brown fat-like phenotype via Soluble Guanylyl Cyclase mediated pathway in vivo and in vitro.
- MondoA Is an Essential Glucose-Responsive Transcription Factor in Human Pancreatic β-Cells.
- Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials.
- Anti-IL-21 monoclonal antibody combined with liraglutide effectively reverses established hyperglycemia in mouse models of type 1 diabetes.
- Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?
- GLP-1 analogue liraglutide attenuates CIH-induced cognitive deficits by inhibiting oxidative stress, neuroinflammation, and apoptosis via the Nrf2/HO-1 and MAPK/NF-κB signaling pathways.
- 2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure: A Report of the American College of Cardiology.
- Weight-centric treatment of type 2 diabetes mellitus.
- Obesity, Cardiovascular Disease, and the Promising Role of Semaglutide: Insights from the SELECT Trial.
- Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis.
- Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes.
- Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.
- Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus.
- Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus.
- Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity.
- Oral Semaglutide Induces Loss of Body Fat Mass Without Affecting Muscle Mass in Patients With Type 2 Diabetes.
- Evidence that tirzepatide protects against diabetes-related cardiac damages.
- Liraglutide, a glucagon-like peptide-1 analog, induce autophagy and senescence in HepG2 cells.
- Exendin-4 promotes the membrane trafficking of the AMPA receptor GluR1 subunit and ADAM10 in the mouse neocortex.
- The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment.
- Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog.
- Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.
- Pharmacologic Treatment of Obesity in Reproductive Aged Women.
- GLP-1 Elicits an Intrinsic Gut-Liver Metabolic Signal to Ameliorate Diet-Induced VLDL Overproduction and Insulin Resistance.
- The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review.
- Dulaglutide mitigates inflammatory response in fibroblast-like synoviocytes.
- High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats.
- Predictors of weight-loss response with glucagon-like peptide-1 receptor agonist treatment among adolescents with severe obesity.
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.